OrbiMed’s iShares Biotechnology ETF IBB Stock Holding History

OrbiMed’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-159,900	Closed	-$13.7M	–	144
2016 Q2	$13.7M	Sell	159,900 -175,200	-52%	-$15.7M	0.14%	86
2016 Q1	$29.1M	Buy	+335,100	New	+$30M	0.31%	59

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

OrbiMed's IBB Position: Q3 2016 in Review

OrbiMed sold out of iShares Biotechnology ETF (IBB) in Q3 2016, closing a stake of 159,900 shares — an estimated $13.7M sold.

OrbiMed first reported a position in IBB in Q1 2016 and held it in 2 quarters. The position peaked at $29.1M in Q1 2016. 463 funds tracked by Wall St. Rank hold IBB as of Q3 2016.

OrbiMed reported no remaining iShares Biotechnology ETF position as of Q3 2016 after selling out during the quarter.
OrbiMed sold 159,900 iShares Biotechnology ETF shares in Q3 2016, an estimated $13.7M.
OrbiMed first reported a position in iShares Biotechnology ETF in Q1 2016 and held it in 2 quarters.
OrbiMed's iShares Biotechnology ETF position peaked at $29.1M in Q1 2016.
463 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2016.

Based on OrbiMed's 13F filing for Q3 2016, filed 14 Nov 2016.